Biohaven Pharmaceutical Holding Company Ltd BHVN:NYSE

Last Price$113.85NYSE Previous Close - Last Trade as of 5:00PM ET 11/26/21

Today's Change-1.70(1.47%)
Bid (Size)$110.00 (1)
Ask (Size)$115.50 (1)
Day Low / High$111.49 - 115.48
Volume448.3 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 11/26/2021


Biohaven Pharmaceutical Holding Company Ltd ( NYSE )

Price: $113.85
Change: -1.70 (1.47%)
Volume: 448.3 K
5:00PM ET 11/26/2021

Allakos Inc ( NASDAQ )

Price: $80.09
Change: -1.13 (1.39%)
Volume: 192.3 K
1:00PM ET 11/26/2021

Apellis Pharmaceuticals Inc ( NASDAQ )

Price: $43.54
Change: -1.47 (3.27%)
Volume: 524.3 K
1:00PM ET 11/26/2021

Karuna Therapeutics Inc ( NASDAQ )

Price: $129.56
Change: -5.09 (3.78%)
Volume: 101.1 K
1:00PM ET 11/26/2021

Reata Pharmaceuticals Inc ( NASDAQ )

Price: $81.40
Change: -3.45 (4.07%)
Volume: 197.5 K
1:00PM ET 11/26/2021

Read more news Recent News

Biohaven Pharmaceutical, Artizan Biosciences Launch Joint Therapeutic Discovery Program for Parkinson's Disease
9:52AM ET 11/18/2021 MT Newswires

Biohaven Pharmaceutical (BHVN) and Artizan Biosciences said Thursday that they are starting a therapeutic discovery program for Parkinson's disease. The...

Mizuho Adjusts Price Target on Biohaven Pharmaceutical to $144 From $135, Keeps Buy Rating
7:19AM ET 11/18/2021 MT Newswires

Biohaven Pharmaceutical Holding Co. (BHVN) has an average investment rating of outperform among analysts polled by Capital IQ, with a price target range of...

Insider Sell: Biohaven Pharmaceutical Holding
6:58AM ET 11/18/2021 MT Newswires

Declan Doogan, Director, on November 16, 2021, sold 37,740 shares in Biohaven Pharmaceutical Holding (BHVN) for $4,402,385. Following the Form 4 filing...

Biohaven Receives Kuwait Regulatory Approval for Migraine Drug Nurtec ODT
2:28PM ET 11/17/2021 MT Newswires

Biohaven Pharmaceutical Holding (BHVN) said that its orally administered drug Nurtec ODT, or rimegepant, has been approved in Kuwait for the treatment of...

Company Profile

Business DescriptionBiohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. View company web site for more details
Address215 Church Street
New Haven, Connecticut 06510
Number of Employees63
Recent SEC Filing11/26/20214/A
Chief Executive Officer & DirectorVladimir Coric
Director-Operations & Regulatory AffairsLisa Stocking
Chief Financial Officer & TreasurerJames Engelhart
Chief Scientific OfficerCharles Conway

Company Highlights

Price Open$112.75
Previous Close$115.55
52 Week Range$62.57 - 151.51
Market Capitalization$7.5 B
Shares Outstanding65.5 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement03/07/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$13.57
Beta vs. S&P 500N/A
Net Profit Margin-281.25%
Return on Equity202.59%

Analyst Ratings as of 08/09/2021

Consensus RecommendationConsensus Icon
Powered by Factset